Drug
mTOR Inhibitor clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
3 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2018 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
University of Miami (1) · Fudan University (1) · Hannover Medical School (1)
Often tested with
Tested in the same studies.
Anastrozole (1) · Fulvestrant (1) · Everolimus (1) · Selective Estrogen Receptor Modulators (1) · Alpelisib (1) · Antineoplastic Agents (1) · Elacestrant (1) · Parpi (1)
Studies
Open first, then newest update. How each study uses mTOR Inhibitor is read from its arms, and is right about nine times in ten.
Testing it · 3
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964Written as mTOR inhibitor + Selective estrogen receptor modulator
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownPhase 1/2Fudan UniversityNCT03805399Written as mTOR inhibitor with nab-paclitaxel
- Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal TransplantStatus unknownPhase 4Hannover Medical SchoolNCT01289301Written as mTOR inhibitor (everolimus)